Califf: Industry Support Will Be Key To FDA’s Prospects Under Trump

How the FDA fares during President-elect Donald Trump’s second term will depend, in part, on the pharmaceutical industry’s support for the agency and its staff, Commissioner Robert Califf told the Friends of Cancer Research annual meeting on Nov. 12.

Califf’s second term as commissioner will end when Trump takes office in January.

“This not the first time I’ve ridden out of town after an election,” he joked.

Califf said the incoming administration clearly is intent on changing a lot of things, but “how it gets changed depends on who gets appointed to the key positions and how the various policies play out.”